XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.3
Restructuring and Other Impairment Activities
 9 Months Ended
Sep. 30, 2024
Restructuring and Related Activities [Abstract]  
Restructuring and Other Impairment Activities Restructuring and Other Impairment Activities
In January 2024, we announced an organizational realignment plan (the "Plan") that is expected to streamline organizational size and complexity and leverage business critical resources to enhance customer support and reduce overhead cost. Restructuring and other impairment expenses related to the Plan were comprised primarily of severance charges. These charges were $0.7 million for the three months ended September 30, 2024, of which $0.2 million, $0.5 million and none incurred within FAM, SAS and Unallocated, respectively, and were $16.4 million for the nine months ended September 30, 2024, of which $3.1 million, $10.0 million and $3.3 million incurred within FAM, SAS and Unallocated, respectively. Restructuring activities associated with the Plan are expected to be completed during 2024, with insignificant additional costs.
Restructuring and other impairment expenses in the FAM segment, excluding costs associated with the Plan were primarily attributable to facility closures announced in prior years. Through September 30, 2024, the FAM Segment has recognized accumulated restructuring and other impairment charges of $5.2 million related to the facility closures. During the remainder of 2024, the Company expects to record additional restructuring costs in the FAM segment of less than $1.0 million related to the closure of these facilities.
Restructuring and other impairment expenses in the SAS segment, excluding costs associated with the Plan included $8.9 million and $16.1 million of impairment charges, for the three and nine months ended September 30, 2024, respectively, to fully impair the net assets at our Eerbeek, Netherlands facility. The impairment assessment was performed after revising our long-term view on cash flows associated with the facility. The remaining restructuring and other impairment expenses were primarily related to a facility closure announced in a prior year. Through September 30, 2024, the SAS segment has recognized accumulated restructuring and other impairment charges of $5.5 million related to the facility closures. During the remainder of 2024, the Company expects to record additional restructuring costs in the SAS segment of less than $1.0 million related to the facility closures.
Assets held for sale of $10.3 million and $10.5 million were included in Other current assets as of September 30, 2024 and 2023, respectively.
The following table summarizes total restructuring and other impairment expense (in millions):
Three Months Ended
September 30,		Nine Months Ended
September 30,
2024202320242023
Filtration and Advanced Materials
Severance and termination benefits$0.3 $— $3.8 $— 
Other exit costs0.4 1.1 1.4 2.3 
FAM restructuring expense0.7 1.1 5.2 2.3 
Sustainable and Adhesive Solutions
Severance and termination benefits0.5 — 10.6 0.1 
Other exit costs1.0 0.2 2.1 0.2 
SAS restructuring expense1.5 0.2 12.7 0.3 
Unallocated
Severance and termination benefits0.1 — 3.4 — 
Unallocated restructuring expense0.1 — 3.4 — 
Total restructuring expense$2.3 $1.3 $21.3 $2.6 
Sustainable and Adhesive Solutions
Other impairment expense8.9 15.0 16.1 15.0 
Total restructuring and other impairment expense$11.2 $16.3 $37.4 $17.6 
The following table summarizes changes in restructuring liabilities (in millions):
20242023
Balance at beginning of the period
$3.8 $4.0 
Charges for restructuring programs
21.3 2.6 
Cash payments and other
(22.3)(3.3)
Balance at September 30, 2024
$2.8 $3.3 
Restructuring liabilities were classified within Accrued expenses and other current liabilities and Other liabilities in the unaudited Condensed Consolidated Balance Sheets.